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Meta-analysis
The prevalence of depression in rheumatoid arthritis:
a systematic review and meta-analysis
Faith Matcham1, Lauren Rayner1, Sophia Steer2 and Matthew Hotopf1
Abstract
Objective. There is substantial uncertainty regarding the prevalence of depression in RA. We conducted a
systematic review aiming to describe the prevalence of depression in RA.
Methods. Web of Science, PsycINFO, CINAHL, Embase, Medline and PubMed were searched for cross-
sectional studies reporting a prevalence estimate for depression in adult RA patients. Studies were
reviewed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) guidelines and a meta-analysis was performed.
Results. A total of 72 studies, including 13 189 patients, were eligible for inclusion in the review. Forty-
three methods of defining depression were reported. Meta-analyses revealed the prevalence of major
depressive disorder to be 16.8% (95% CI 10%, 24%). According to the PHQ-9, the prevalence of de-
pression was 38.8% (95% CI 34%, 43%), and prevalence levels according to the HADS with thresholds of
8 and 11 were 34.2% (95% CI 25%, 44%) and 14.8% (95% CI 12%, 18%), respectively. The main
influence on depression prevalence was the mean age of the sample.
Conclusion. Depression is highly prevalent in RA and associated with poorer RA outcomes. This suggests
that optimal care of RA patients may include the detection and management of depression.
Key words: depression, rheumatoid arthritis, prevalence, meta-analysis, systematic review.
Introduction
Depression is more common in RA than in the general
population [1] and has been associated with increased
pain [2], fatigue [3], reduced health-related quality of life
[4], increased levels of physical disability [5] and increased
health care costs [6]. Depressed RA patients have poorer
long-term outcomes, including increased pain [7], more
comorbidities [8] and increased mortality levels [9].
Depression may therefore be a useful target for interven-
tions aimed at improving subjective health and quality of
life in RA patients. However, prevalence estimates for de-
pression in RA range between 9.5% [10] and 41.5% [11],
making it difficult to establish the likely impact of depres-
sion in this patient group.
There are various reasons why this variation in preva-
lence estimates may exist. First, the term depression is
not clear-cut. Making sense of depressive symptoms in
the context of chronic physical disease is challenging—it
may be difficult to distinguish between patients with a
depressive disorder, as opposed to those demonstrating
a normal reaction to living with a chronic, debilitating
condition. Further, a number of somatic symptoms of
depression (e.g. fatigue, poor sleep and loss of appetite)
might be expected to occur in RA as part of the disease
process. To overcome this, researchers have adapted
diagnostic thresholds to define caseness [12] or removed
items that may be confounded by RA symptoms, for ex-
ample, items assessing fatigue or sleep quality [13]. Such
variations in definitions of depression may influence
prevalence estimates.
Second, there are a multitude of methods available to
detect depression. The gold standard method is psychi-
atric interview and diagnosis according to Diagnostic and
Statistical Manual (DSM) [14] or International Class-
ification of Diseases (ICD) [15] criteria. However, such
interviews are time consuming and expensive and there-
fore often not ideal for examining patients in a busy hos-
pital environment [16]. Alternatively, self-report screening
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questionnaires, such as the Patient Health Questionnaire
(PHQ) [17] and the Hospital Anxiety and Depression Scale
(HADS), may be used. These self-report tools are quick
and easy to complete, meaning they are often preferred
by researchers attempting to collect a large amount of
data from a large sample; they are also cheaper to use
than diagnostic interviews. Prevalence estimates accord-
ing to screening tools are often based on predefined
thresholds, which may result in overestimations of preva-
lence, as screening questionnaires tend to prioritize sen-
sitivity over specificity [16].
Study quality may be a further explanation for the vari-
ance in prevalence estimates. Small studies lead to vari-
able and imprecise prevalence estimates. Sampling
strategies may influence prevalence estimates, with
studies using convenience sampling or low participation
rates giving unrepresentative samples that may be heal-
thier than the target population [18]. Furthermore, the
population studied can impact prevalence estimates;
some studies may include patients with specific disease
durations, or those using a particular type of medication,
which may impact prevalence levels [19, 20].
There has only been one previous systematic review of
depression in RA, which examined the strength of the as-
sociation between depression and RA [21]. As yet no sys-
tematic review has provided pooled prevalence estimates
of depression in RA. The present study aims to fill this
gap. We aimed (i) to present a pooled prevalence level
of depression in RA patients; (ii) to provide a summary
of the methods used to define depression in RA and (iii)
to explore the impact of study characteristics on preva-
lence estimates.
Materials and methods
Search strategy and selection criteria
The systematic review protocol and data extraction forms
were designed in accordance with the Preferred Reporting
Items for Systematic reviews and Meta-Analyses (PRISMA;
[22]) by F.M. and L.R. F.M. conducted a systematic search
of Web of Science, CINAHL, PsycINFO, Medline, Embase
and PubMed, from inception to October 2012. Sample
search terms can be found in supplementary Appendix
S1, available at Rheumatology Online.
Inclusion and exclusion criteria
Studies met the following inclusion criteria: (i) Cross-sec-
tional design, baseline cross-sectional data from a longi-
tudinal study or baseline cross-sectional data from a trial,
before group allocation. (ii) Reported a prevalence level for
depression using diagnostic criteria, a research diagnostic
tool or a validated screening tool (Table 1). (iii) Reported
prevalence level as the number of participants meeting
predefined criteria for depression, or a percentage from
which the number of participants meeting criteria for
depression could be calculated. (iv) The sample size
was 550.
Studies were excluded if they: (i) used a selective
sample (e.g. intervention trials after group allocation);
(ii) used a paediatric sample; (iii) retrospectively reviewed
medical records to establish depressive symptomatology.
For the meta-analysis, studies using a screening tool
without stating the cut-off threshold used to detect
depression were excluded. Table 2 provides a full list of
the eligible methods of detecting depression, alongside
the numbers of articles utilizing each method and the
number of participants assessed.
Data extraction and quality assessment
F.M. conducted the primary data extraction. All articles
were examined independently by a second reviewer
(L.R.). Inter-rater disagreement was minimal, and any dis-
agreements were resolved through discussion and reexam-
ination of the article in consultation with M.H. When multiple
publications spanned the years of longitudinal studies,
baseline prevalence levels were reported. A 10-point quality
assessment tool (supplementary Appendix S2, available at
Rheumatology Online) was devised to assess sampling
method, sample size, participation rate, criteria used to de-
termine depression and the eligibility criteria for participa-
tion in the studies. Articles were scored as follows:
03 = low quality; 46 = low to medium quality; 78 = me-
dium to high quality; 910 = high quality.
Outcome measures
Outcomes were major depression, minor depression,
depressive/mood/affective disorder, dysthymic disorder
or adjustment disorder, defined by diagnostic interview
or according to a defined threshold on a screening tool.
Statistical analyses
Data were pooled according to diagnosis of depression or
screening tool and threshold used to detect caseness.
Heterogeneity was found to be moderately high between
studies, and therefore random-effects meta-analyses with
95% CIs were conducted with STATA (version 10.0).
Heterogeneity was assessed using I2, with thresholds of
525%, 550% and 575% indicating low, moderate and
high heterogeneity, respectively [23].
Sensitivity analyses explored whether prevalence esti-
mates were influenced by study design. Planned sensitivity
analyses included the following: exclusion of studies with a
participation rate 475%, or non-reported participation
rate; exclusion of studies not stating a sampling strategy,
or using a convenience/non-randomized sampling strategy;
exclusion of studies that did not state eligibility criteria for
inclusion in the study and exclusion of studies using sub-
sets of patients (for example, a female-only sample or pa-
tients with limited disease duration). Subgroup analyses
were planned by overall study quality, sample size, country
of origin and publication year, if there was more than one
study in the subgroup. Spearman’s correlation analyses
with adjusted r2 assessed the impact of study variables
on prevalence estimates. Funnel plots were produced to
explore the possibility of publication bias due to preferential
publication of small studies reporting high prevalence esti-
mates; Begg-Mazumdar and Egger’s tests of publication
bias were also performed.
www.rheumatology.oxfordjournals.org 2137
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Results
Search results
The search yielded 28 328 relevant articles (Fig. 1). After
removal of duplicates, titles and then abstracts were
screened for potential eligibility. All non-RA articles were
removed, resulting in 806 potentially eligible studies.
These were screened according to the inclusion and
exclusion criteria for entry into the study, resulting in a
total of 101 eligible studies. After taking into account mul-
tiple publications from the same sample, 72 articles were
included in the review.
Included studies
Table 1 presents the 72 papers included in the review (see
supplementary Appendix S3, available at Rheumatology
Online). Seven studies used diagnostic criteria (DSM or
ICD), and the remaining 66 used (one or more) screening
TABLE 2 Methods of detecting depression and summary of prevalence and heterogeneity findings
Tool Definition/threshold
No. of
studies
No. of
participants
Prevalence, %
(95% CI) Heterogeneity I2, %
Diagnostic criteria
DSM Major depression 4 480 16.8 (10, 24) 73.4
Dysthymic disorder 3 420 18.7 (2, 39) 97.2
Unspecified depression 2 280 6.4 (4, 17) 88.1
Depressive disorder 1 200 1.5 —
Adjustment disorder
and depression
1 200 0.5 —
ICD-10 Unspecified depression 1 80 66.3 —
Screening questionnaires
Beck Depression
Inventory (BDI)
10 2 129 34.9 (27, 43) 0.0
15 1 50 46.0 —
16 1 60 63.3 —
19 1 52 23.0 —
30 1 52 2.0 —
BDI-SFa 8 1 75 22.0 —
BDI-pcb 4 1 228 7.0 —
Centre for Epidemiological
Studies Depression
Scale (CESD)
9 1 77 31.2 —
10 1 426 29.8 —
12 1 141 13.0 —
15 2 301 36.2 (31, 42) 0.0
16 14 3333 36.0 (32, 40) 83.1
17 1 725 20.3 —
19 2 142 37.9 (30, 46) 0.0
23 1 125 16.0 —
27 1 148 7.4 —
CESD-13c 9 1 92 26.6 —
13 1 92 8.1 —
Geriatric Depression Scale
(GDS)
5 1 461 2.0 —
10 1 461 11.0 —
S-GDSd 7 1 726 14.0 —
GDS-5e 2 1 98 24.5 —
Hospital Anxiety and
Depression Scale (HADS)
7 3 536 48.0 (9, 87) 98.5
8 7 1193 34.2 (25, 44) 90.9
9 3 583 32.1 (14, 50) 94.4
10 4 344 14.9 (4, 26) 90.9
11 12 2398 14.8 (12, 18) 74.0
15 1 509 4.5 —
Inventory to Diagnose
Depression (IDD)
DSM-III 1 74 27.0 —
DSM-III-R 1 74 16.2 —
DSM-IV 1 58 14.0 —
Patient Health
Questionnaire
(PHQ-9)
10 2 659 38.8 (34, 43) 19.8
Self-Rating
Scale (SRS)
40 2 726 52.6 (52, 60) 1.8
48 2 98 35.3 (31, 40) 0.0
aBDI Short Form; bBDI for Primary Care; c13-item CES-D; dShort GDS; e5-item GDS.
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tools to detect depression (PHQ-9, IDD, HADS, CESD,
BDI, SDS or GDS), the most popular being the HADS
and the CESD. The studies represented a total of 13 189
patients with RA; the median of mean ages was 53.7 years
[interquartile range (IQR) 51.056.5], and the median per-
centage of females represented in the sample was 77.0%
(IQR 70.482.9%). Sample sizes ranged from 50 to 988
participants (median = 96.0; IQR 75.0159.0).
Quality assessment
Table 1 presents the quality assessments for the 72
papers, according to the quality assessment tool (supple-
mentary Appendix S2, available at Rheumatology Online).
The overall quality of the articles was poor with a median
quality score of 3/10 (IQR 15). Eleven papers (15%)
scored 0/10, and 82% of papers scored 5/10 or lower.
No papers achieved the maximum score of 10; however,
one received 9 out of 10 [10]. Specifically, 16.6% of
studies had a sample size larger than 300, only 41.7%
stated a participation rate and of these, only 40% had a
participation rate575%. Only 55.6% reported participant
eligibility criteria for entry into the study.
Defining depression
Depression was defined in 40 different ways (Table 2). The
studies using diagnostic interviews reported three differ-
ent subtypes of depression: major depressive disorder
(MDD), minor depression (MD) and dysthymic disorder
(DD), as well as combinations of disorders (depression
with adjustment disorders or anxiety) and unspecified de-
pression. Studies using screening questionnaires defined
possible or probable caseness using multiple thresholds
or detected any depression using one threshold.
According to diagnostic criteria, MDD and DD were the
most commonly diagnosed depressive subtypes. A full
explanation of the differences between depressive diag-
noses can be found in supplementary Appendix S4,
available at Rheumatology Online.
The most commonly used screening questionnaire was
the HADS, with 30 studies using this screening tool.
However, six different thresholds were presented in the
FIG. 1 Search results and study selection.
Reasons for exclusion at data extraction include:  
- Sample size <50 
- Combination of depression and anxiety into 
one psychological distress outcome.  
-  Depression measured post-intervention in 
trials. 
- Prevalence estimated from number of clinic 
visits as opposed to number of patients.  
856 non-RA papers excluded 806 potentially eligible RA papers 
Web of Science 
6,936 
PubMed 
1,434
CINAHL 
1,248 
PsycINFO
2,323 
Medline 
5,436
Embase 
10,951
Total search result:  
28,328 publications 
12,007 duplicates removed 16,321 titles screened 
14,695 papers excluded 1,662 abstracts screened 
652 did not meet inclusion criteria 154 papers included for data 
extraction 
53 papers excluded at data extraction 101 eligible for inclusion in 
review. 
Condensed into one prevalence estimate per study 
sample: 
TOTAL = 72
29 duplicate publications  excluded 
Common reasons for 
exclusion: 
- Ineligible measurement of 
depression (N= 147). 
-Intervention or literature 
review (N=119). 
-Measuring psychological 
distress instead of 
depression (N=70). 
Additionally, 32 potentially 
eligible papers were 
excluded, as their full texts 
could not be accessed, and 
their abstracts did not 
contain enough information 
for inclusion.
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articles, with the conventional cut-offs of 8 (probable
depression) and 11 (definite depression) being the most
commonly used. Twenty-five articles used the CESD; nine
different cut-off points were presented, the most com-
monly used being 16. Eight papers used the BDI, with
five different thresholds for depression.
Prevalence of depression
Prevalence of depression alone (excluding combination
disorders) ranged between 0.04% and 66.3% in individ-
ual studies (Table 1). Table 2 presents the summary
of meta-analyses and heterogeneity assessments.
Meta-analytical pooled prevalence of MDD (Fig. 2) ac-
cording to the DSM diagnostic criteria was 16.8% (95%
CI 10.0%, 24.0%), with moderate heterogeneity
(I2 = 73.4%). Dysthymic disorder (according to DSM criteria)
showed a pooled prevalence level of 18.7% (95% CI
2.0%, 39.0%), with high heterogeneity (I2 = 97.2%).
Prevalence of depression according to the PHQ-9, with
a threshold of 10 indicating moderate-severe depressive
symptoms, was 38.8% (95% CI 34.0%, 43.0%), with low
heterogeneity (I2 = 19.8%).
Analyses of screening questionnaires according to the
threshold used to detect depression were conducted. As
FIG. 2 Prevalence of MDD in RA.
 Prevalence
 0 70.2%
 Study 
Prevalence
(95% CI) % Weight
MDD measured through DSM criteria
Abdel-Nasser 1998 23% (13-34%) 8.1 
Frank 1988 17% (11-23%) 23.7 
Lok 2010 9% (5-14%) 56.3 
Uguz 2009 22% (13-31%) 11.8 
Pooled Prevalence   17% (10-24%) 100.0 
HADS (threshold of 8) 
Barlow 1999 28% (20-37%) 9.2 
Chang 2007   41% (36-45%) 38.5 
Covic 2009  23% (14-31%) 9.5 
Dirik 2010 56% (47-65%) 8.7 
Hewlett 1995  20% (9-31%) 5.7 
Hider 2009 47% (40-55%) 11.7 
Pincus 1996 23% (17-30%) 16.7 
Pooled Prevalence 34% (25-44%) 100.0 
HADS (threshold of 11)
Barlow 1999 15% (8-22%) 4.5 
Chang 2007 18% (15-22%) 18.5 
Chow 2001 17% (10-25%) 3.6 
 Covic 2009 10% (4-16%) 5.7 
Hanly 2005 4% (-1-9%) 8.0 
Hewlett 2002 20% (12-29%) 3.1 
Ho 2011 15% (8-22%) 4.3 
 Mo 2010 10% (4-16%) 5.8 
Pincus 1996 15% (10-21%) 6.9 
Pinheiro 2010 21% (17-24%) 16.8 
Scott 2007 18% (15-22%) 19.5 
Worral 2007 11% (3-19%) 3.3 
Pooled Prevalence 15% (12-18%) 100.0 
CESD (threshold of 16)
Covic 2006 40% (32-49%) 3.9 
Covic 2009 46% (35-56%) 2.6 
Escalante 2000 42% (36-49%) 6.8 
Fifield 1992 32% (29-35%) 31.8 
Goodenow 1990 23% (17-29%) 7.8 
 Kobayashi-Gutierrez 2009 27% (17-36%) 2.9 
MacKinnon 1998 29% (21-36%) 4.9 
Massardo 2001 47% (35-58%) 2.1 
 6.1 
 3.1 
 3.9 
 2.8 
4.8  
16.5 
100.0
Penninx 1996             41% (35-48%) 
Revenson 1991             36% (26-45%) 
Rivero-Carrera 2011             29% (21-38%) 
Wilkins 2000             60% (51-70%) 
Wright 1996             30% (22-37%) 
Wright 1998             30% (26-34%) 
Pooled Prevalence             36% (32-40%) 
Pooled prevalence of MDD according to DSM criteria in RA patients by random effects meta-analysis.
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expected, higher thresholds yielded lower prevalence es-
timates. For example, the HADS shows an estimated
prevalence of 34.2% when used with a threshold of 8,
and a prevalence of 14.8% when used with a threshold
of 11 (Fig. 2).
Assessment of publication bias (see supplementary
Appendix S5, available at Rheumatology Online) indicated
significant publication bias, according to the Egger’s test,
in studies reporting MDD according to DSM criteria
[Begg-Mazumdar: Kendall’s  = 1.36, P= 0.17, Egger:
bias = 4.59 (95% CI 1.36%, 7.82%), P= 0.03]. There was
no significant evidence of publication bias in any other
analyses.
Sensitivity and subgroup analyses
Table 3 shows prevalence estimates according to each
sensitivity and subgroup analysis, in comparison with
the primary analysis. The results of the sensitivity analyses
indicated no particular trend or pattern according to the
exclusion of studies with only abstracts available, the ex-
clusion of studies with unreported participation rates or
participation rates 475%, the removal of studies using
convenience, non-randomized, or with unreported sam-
pling strategies, or the exclusion of studies using subsets
of patients. Exclusion of studies with no reported eligibility
criteria tended to increase prevalence estimates, with the
exception of the CESD (threshold 16). The subgroup ana-
lyses were conducted according to sample size, overall
quality and publication year. The subgroup analyses for
sample size and overall quality showed no clear patterns.
However, more recent publications tended to yield higher
prevalence estimates.
Associated study variables
Spearman’s correlation analyses with adjusted r2 were
used to assess the associations between linear variables
including participation rate, sample size, overall study
quality, publication year, proportion of female partici-
pants, mean age of participants and mean duration of ill-
ness. Table 4 shows the results of these analyses.
A significant relationship was found between mean age
and prevalence estimate; lower age was associated with
increased depression prevalence (r=0.3, P= 0.02). No
other study characteristics showed a significant associ-
ation with prevalence estimate.
Discussion
Depression is highly prevalent in RA patients. Estimates
varied according to the way in which depression was
measured, but our pooled estimates from the small
number of studies using gold standard clinical interviews
suggest that major depression is present in 16.8% of RA
patients. The larger number of studies using screening
tools found significant depressive symptoms present in
38.8% using the PHQ-9 and between 14.8% and 48%
using the HADS. These prevalence estimates are consid-
erably higher than those observed in the general popula-
tion [1] and are similar to, or higher than, those observed
in patients with diabetes [24], Parkinson’s disease [25] and
cancer [26]. Although studies varied widely in terms of
quality (and many were of poor quality), our sensitivity
analyses indicate that prevalence estimates were reason-
ably stable. Apart from the measurement tool used to as-
certain depression, study quality and study population
had little impact on the estimates detected.
The RA patient population represents a largely female,
older adult population [27]. It could be suggested that the
inflated levels of depression found in this sample repre-
sent the increased risk of depression found in females and
the elderly [28, 29], regardless of the presence of RA.
However, as we found a significant negative association
between age and depression prevalence estimate, it is
more likely that our findings represent and increased risk
of depression in RA patients in comparison with the gen-
eral population.
A bewildering diversity of assessment measures were
used to ascertain depression. This is similar to the situ-
ation in other physical diseases [30]. In this review, we did
not include many studies that did not use validated meas-
ures of depression or questionnaires that assess a
broader overlapping concept of psychological distress.
Nevertheless we found that many studies used idiosyn-
cratic cut-off scores on screening tools, meaning that the
range of estimates for one such measure (the HADS)
varied from 14.8% to 48%. Because there have not
been validation studies to determine the best cut-point
for such screening tools in this population, one clear rec-
ommendation is that investigators justify the use of idio-
syncratic thresholds, and always report prevalence at
conventional cut-points as well, to allow cross-study
comparisons.
We used rigorous methods to conduct the review, with
a sensitive search, and a reproducible, structured ap-
proach to data extraction and synthesis. We took a
broadly inclusive approach to inclusion of studies, prefer-
ring to include less rigorous studies and explore the
impact of study design in sensitivity analyses than to ex-
clude such studies from the outset. It is possible that pub-
lication bias affected our results. We explored this using
funnel plots and Egger’s test where the assumption made
was that small studies reporting low prevalence of de-
pression would be less likely to be published than small
studies reporting high prevalence. We only found evi-
dence of potential publication bias in the studies that
used diagnostic interviews. This is surprising since the
efforts taken to conduct such studies are considerable
and we would have anticipated these to be least likely
to be affected by publication bias.
There are, however, additional important shortcomings
in the evidence on prevalence of depression in RA that
need to be addressed. The limited number of studies
using structured clinical interview and determining de-
pression according to DSM and ICD criteria is a concern.
The high rates of depressive symptomatology detected
through the screening tools could be due to the overlap
between the somatic symptoms of depression and symp-
toms of RA. Symptoms frequently associated with
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depression (such as fatigue and reduced sleep quality)
may be experienced by RA patients regardless of whether
depressive symptoms are present or not. For example, 7
out of the 21 BDI items assess somatic symptoms, lead-
ing to concerns about the validity of this questionnaire in
medical patients [31]. Similarly, a modified version of the
CESD has been suggested for use with patients with RA,
due to the symptom overlap [32]; however, only two art-
icles in the current review used the modified versions
available [33, 34].
A further consideration is the representativeness of the
sample from which prevalence levels are estimates.
Low socio-economic status (SES) patients are often
under-represented in research samples [35]. This can be
problematic, as low SES is associated with increased sus-
ceptibility to depression [36] and RA [37]. Many of the
studies included in this review did not measure SES
appropriately, with most studies using a single measure
of education level or monthly income to indicate SES. This
level of heterogeneity makes it difficult to establish the
representativeness of the samples included with regard
to SES. However, it is possible that a selection bias
favouring high SES patients exists and the results of this
systematic review may therefore underestimate the preva-
lence of depression.
The meaning of depression in the context of RA is not
straightforward. Emotional responses to a physical illness
characterized by pain and debility are understandable,
and somatic symptoms of depression (e.g. loss of appe-
tite and poor sleep) might be expected as part of RA.
Therefore there is a need to ensure that measures of de-
pression used in clinical practice are validated, both
against a recognized criterion (e.g. the ‘gold standard’
clinical interviews) and also in terms of predictive validity
(i.e. to determine the impact of depression on RA out-
comes). Psychometric approaches utilizing longitudinal
data may further be able to distinguish subtypes of de-
pressive symptoms and thereby distinguish symptoms
that are most likely to be core to the depressive
syndrome.
Ultimately the key question is whether improved patient
outcomes can be attained by recognizing and managing
depression more effectively. There is growing evidence
that incorporating a system of collaborative and stepped
care of depression in patients with physical illness, which
might include routine screening for depression with refer-
ral for highly structured manualized therapies depending
on the outcome of screening, is effective treatment [38].
The high prevalence of depression in RA suggests that
this would be a suitable patient group in which to test
such strategies.
Rheumatology key messages
. Depression is highly prevalent in RA patient groups.
. Increased depression prevalence in RA is signifi-
cantly associated with low mean age.
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